UNSPSC 51333403: Blonanserin

This classification denotes a serotonin antagonist with the molecular formula C23H30FN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, AQ316B4F8C chemically known as 2-(4-ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine but generally known as blonanserin, which bears US NIH Compound Identifier 125564. European Medicines Agency schedules Blonanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05864MIG.

UNSPSC 51333403 Blonanserin is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and drug-related medical supplies, though the posted opportunity shows a mismatch with the code's nominal pharmaceutical scope. Seminole County, Florida's June 2026 solicitation (IFB60459723LAS) was tagged under this code but actually seeks Naloxone and Safe Drug Deactivation Systems — community health and emergency response supplies rather than the antipsychotic medication the code nominally describes. State and local procurement offices appear to use this code inconsistently or the recent opportunity was miscategorized. The source shows limited recent activity, with only one posted state or local opportunity matching this code in the dataset.

Seminole County, a Florida county government, issued the Naloxone and Safe Drug Deactivation Systems procurement as a competitive IFB with a response deadline of July 26, 2023, seeking 1,900 units of Naloxone and 800 deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must provide unit costs, comply with drug-free workplace and E-Verify requirements, carry workers' compensation and general liability insurance, and accept a three-month probationary termination-at-will clause. The contract includes a two-year initial term with a one-year renewal option. Given the sparse recent-opportunity record and the categorical mismatch between the code name and the actual procurement scope, this code warrants close monitoring to determine whether it reflects genuine state and local buying activity in antipsychotic pharmaceuticals or represents a data classification issue.